
Forecast: Biotech Will Get Up Close And Personal In 2023 With More Funding To The ‘Omics’
The “omics” — genomics, transcriptomics, metabolomics and proteomics — are booming in biotech, with more big raises expected in 2023.
Dealmakers think 2023 could see a significant jump in M&A volume as companies’ options for money and exits dwindle.
Despite 2022’s pullback in venture capital funding, 10 companies in the U.S. still broke the $1 billion barrier in individual raises.
After two years of pandemic-fueled valuations, public market climbs and billions in venture funding, bloated tech companies big and small are now…
For 2023, we’re predicting that startup investors will be looking for novelty in the companies they back. Out with the me-too business plans.
Venture firms have continued to raise record funds in 2022, even as startups received far less money. So what will happen with all that dry powder in…
With layoffs, massive funding pullbacks and an overall sense of doom clouding the economy, we naturally saw attention drawn to our coverage of those…
This year hasn’t exactly been a blockbuster for the IPO markets. Venture funding has tanked and fewer startups have dared to step into the public…
More than 91,000 workers in the U.S. tech sector have been laid off in mass job cuts so far in 2022, according to a Crunchbase News tally.
Now that the end of the year is fast approaching, let’s look at the five most interesting rounds of the year — at least in our eyes.
For startups in times like these, Series A is a good place to be. However, given the dropoff after Series A, startups might get stuck unless Series B…
For 2023, we’re predicting that startup investors will be looking for novelty in the companies they back. Out with the me-too business plans.